8th OLOMOUC NEUROIMMUNOLOGY SYMPOSIUM
WITH INTERNATIONAL PARTICIPATION
September 20 – 21, 2012
Konvikt – Arts Centre, Palacký University, Olomouc
MAIN TOPICS:
- Treatment Optimization in Multiple Sclerosis
- Intravenous Immunoglobulins in Neuroimmunological Diseases
- Multiple Sclerosis
- Cerebrospinal Fluid Session
- Nurse Session
Programme
September 20, 2012
15.00 AUDITORIUM: Topical Symposium NEOMED – The Role of Botulotoxin A in the Treatment of Neurogenic Bladder
Chair: Študent V.
15.00 | Urological findings in patients with MS |
15.15 | What can urologist offer the patients with MS? |
15.30–15.45 Break
15.45 AUDITORIUM: Launch Symposium Biogen Idec – Avonex PEN
Chair: Horáková D.
15.45 | Avonex PEN – greater comfort and less pain in the treatment of MS |
16.00 | Long-term effect on 1st and 2nd line treatment of MS |
16.15 | The importance of symptomatic therapy for quality of life of patients with MS |
16.30–17.00 Break
17.00 AUDITORIUM: The Opening Ceremony of the Symposium
Assoc. Prof. Dr. Jan Mareš, PhD. – General Co-Chair of the Symposium
Welcome:
Prof. Dr. Petr Kaňovský, CSc. – Vice President of Czech Neurological Society CLS JEP and Head of Dept. of Neurology Faculty of Medicine Palacký University and University Hospital in Olomouc
Prof. Dr. Eva Havrdová, CSc. – Vice President of Section for Neuroimmunology and Cerebrospinal Fluid of CNS CLS JEP and General Co-Chair of the Symposium
Dr. Radomír Taláb, CSc. – President of Section for Neuroimmunology and Cerebrospinal Fluid of CNS CLS JEP
Prof. Dr. Miroslav Mašláň, CSc. – Rector of Palacký University in Olomouc
Prof. Dr. Milan Kolář, PhD. – Dean of the Faculty of Medicine of Palacký University in Olomouc
Assoc. Prof. Dr. Roman Havlík, PhD. – Director of University Hospital in Olomouc
Ing. Martin Tesařík – Olomouc Region Governor
Martin Novotný – Mayor of the City of Olomouc
17.20 AUDITORIUM: Treatment Optimization in Multiple Sclerosis
Chairs: Štourač P., Mareš J.
17.20 | NABs testing in IFNbeta treatment |
18.00 | Risk stratification and STRATIFY JCVTM Expert Statement |
18.40 | Managing fingolimod in clinical practice: The Dresden experience |
19.30 | Welcome Reception – Courtyard Konvikt – Arts centre, Palacký University, Olomouc |
September 21, 2012
8.00 AUDITORIUM: Topical Symposium – Intravenous
Immunoglobulins in Neuroimmunological Diseases
Chairs: Zapletalová O., Piťha J.
8.00 | The mechanism of action of immunoglobulins in autoimmune diseases |
8.15 | Intravenous immunoglobulins in the treatment of multiple sclerosis |
8.30 | Intravenous immunoglobulins in the treatment of myasthenia gravis |
8.45–9.15 Break
9.15 AUDITORIUM: Multiple Sclerosis I
Chairs: Štětkářová I., Přikrylová Vranová H.
9.15 | Progressive multifocal leukoencephalopathy in patients with MS treated with natalizumab: Case report |
9.45 | Natalizumab, optimization of treatment, minimize the risk |
10.00 | Clinical and MRI predictors of disability accumulation in MS – the possibilities of influencing |
10.15 | Atrophy in Multiple Sclerosis |
10.30 | Effect of DMD application methods to adherence and effectiveness in treatment MS |
10.45 | The prevalence of pain in patients with multiple sclerosis |
11.00–11.30 Break
11.30 AUDITORIUM: Multiple Sclerosis II
Chairs: Havrdová E., Taláb R.
11.30 | Effect of immunomodulatory treatment on the natural history of MS |
12.00 | Comprehensive monitoring of MS – early indicators of persisting disease activity |
12.15 | Importance of evoked potentials for diagnostics and monitoring of MS |
12.30 | Monitoring of MXA mRNA expression as a marker of biological activity of interferon beta – preliminary results of one year follow-up |
12.45 | Vitamin D and MS |
13.00 Lunch – end of the symposium
September 21, 2012
8.00 LECTORIUM: CSF Session
Chairs: Sládková V., Čuchran P.
8.00 | CSF cytology |
8.15 | The importance of CSF analysis of energy metabolism parameters of glucose in patiens with MS |
8.30 | Degenerative markers in the cerebrospinal fluid of MS patients |
8.45–9.15 Break
8.00 CINEMA HALL: Nurse Session
Chairs: Pyciaková L., Kalandrová L.
8.00 | Sativex – progress in the symptomatic treatment of multiple sclerosis |
8.15 | Investigation of MxA and education of MS nurses in Europe |
8.30 | Risks of MS treatment from the perspective of nurses |
8.45 | Effective education of MS patients – cooperation with external patient support program |
9.00–9.15 Break